Innate Pharma Announced That The US FDA Has Cleared Its Investigational New Drug (IND) Application To Initiate A Phase 1 Clinical Study Of IPH4502, A Nectin-4 ADC To Be Developed In Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma has received clearance from the US FDA for its IND application to start a Phase 1 clinical study of IPH4502, a Nectin-4 ADC, for solid tumors.
September 23, 2024 | 6:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Innate Pharma's IND application for IPH4502, a Nectin-4 ADC, has been cleared by the US FDA, allowing the start of a Phase 1 clinical study in solid tumors.
The FDA clearance is a significant regulatory milestone for Innate Pharma, allowing them to proceed with clinical trials. This positive development could boost investor confidence and potentially lead to an increase in IPHA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100